amsacrine has been researched along with paclitaxel in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (33.33) | 18.2507 |
2000's | 6 (40.00) | 29.6817 |
2010's | 4 (26.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kwon, Y; Park, S | 1 |
Tritton, TR; Vichi, PJ | 1 |
Holm, B; Jensen, PB; Sehested, M | 1 |
Baguley, BC; Davey, MW; Davey, RA; Hargrave, RM; Harvie, RM; Su, GM | 1 |
Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R | 1 |
Dhawan, V; Swaffar, DS | 1 |
Davey, M; Davey, R; Locke, V | 1 |
Bacherikov, VA; Chen, CH; Chou, TC; Dong, HJ; Lin, YW; Su, TL; Tsai, TJ | 1 |
Goldman, A; Pommier, Y; Sordet, O | 1 |
15 other study(ies) available for amsacrine and paclitaxel
Article | Year |
---|---|
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Molecular Structure; Polymerization; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin | 2018 |
Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A.
Topics: Amsacrine; Animals; Biological Transport; Brefeldin A; Cell Survival; Cyclopentanes; DNA Damage; DNA Repair; Doxorubicin; Drug Synergism; Endoplasmic Reticulum; Etoposide; Golgi Apparatus; Kinetics; Leukemia L1210; Mice; Microtubules; Nocodazole; Paclitaxel; Temperature; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship | 1996 |
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide to circumvent three multidrug-resistance phenotypes in vitro.
Topics: Acridines; Amsacrine; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Buthionine Sulfoximine; Cell Line; Cell Survival; Daunorubicin; Drug Resistance, Multiple; HL-60 Cells; Humans; Idarubicin; Leukemia; Paclitaxel; Phenotype; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |
Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Butyrates; Butyric Acid; Camptothecin; Carboplatin; Cisplatin; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Paclitaxel; Retinoblastoma; Suramin; Tumor Cells, Cultured | 1998 |
A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIalpha.
Topics: Amsacrine; Animals; Antigens, Neoplasm; Catalysis; Cattle; CHO Cells; Cricetinae; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Isoenzymes; Kinetics; Paclitaxel; Topoisomerase II Inhibitors | 1999 |
Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Cell Cycle; Cell Survival; Chlorambucil; Cisplatin; Daunorubicin; Drug Resistance, Multiple; Epirubicin; Genistein; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
Topics: Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Injections, Intravenous; Mice; Mice, Nude; Nitrogen Mustard Compounds; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured; Vinblastine; Xenograft Model Antitumor Assays | 2004 |
Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes.
Topics: Amino Acid Chloromethyl Ketones; Amsacrine; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Enzyme Inhibitors; Etoposide; HL-60 Cells; Humans; Paclitaxel; Reactive Oxygen Species; Topoisomerase II Inhibitors; Tubulin Modulators; Vinblastine | 2006 |